Page last updated: 2024-09-03

y 27632 and Graves Ophthalmopathy

y 27632 has been researched along with Graves Ophthalmopathy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Liao, SL; Wang, CC; Wang, SH; Wei, YH; Yang, CH	1

Other Studies

1 other study(ies) available for y 27632 and Graves Ophthalmopathy

Article	Year
Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves' Ophthalmopathy-Derived Orbital Fibroblasts Frontiers in endocrinology, 2020, Volume: 11 Topics: Adult; Amides; Cell Differentiation; Female; Fibrosis; Graves Ophthalmopathy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; Middle Aged; Myofibroblasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Primary Cell Culture; Pyridines; rho-Associated Kinases; rhoA GTP-Binding Protein; Simvastatin; Transforming Growth Factor beta	2020

Article

Year

Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves' Ophthalmopathy-Derived Orbital Fibroblasts

Frontiers in endocrinology, 2020, Volume: 11

Topics: Adult; Amides; Cell Differentiation; Female; Fibrosis; Graves Ophthalmopathy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; Middle Aged; Myofibroblasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Primary Cell Culture; Pyridines; rho-Associated Kinases; rhoA GTP-Binding Protein; Simvastatin; Transforming Growth Factor beta

2020